These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

727 related items for PubMed ID: 23675525

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.
    Duan Y, Chen Y, Hu W, Li X, Yang X, Zhou X, Yin Z, Kong D, Yao Z, Hajjar DP, Liu L, Liu Q, Han J.
    J Biol Chem; 2012 Jul 06; 287(28):23667-77. PubMed ID: 22593575
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor.
    Romagnuolo R, Scipione CA, Boffa MB, Marcovina SM, Seidah NG, Koschinsky ML.
    J Biol Chem; 2015 May 01; 290(18):11649-62. PubMed ID: 25778403
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification.
    Tveten K, Holla ØL, Cameron J, Strøm TB, Berge KE, Laerdahl JK, Leren TP.
    Hum Mol Genet; 2012 Mar 15; 21(6):1402-9. PubMed ID: 22156580
    [Abstract] [Full Text] [Related]

  • 15. Common Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function.
    DeVay RM, Yamamoto L, Shelton DL, Liang H.
    PLoS One; 2015 Mar 15; 10(4):e0125127. PubMed ID: 25905719
    [Abstract] [Full Text] [Related]

  • 16. PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.
    Ason B, van der Hoorn JW, Chan J, Lee E, Pieterman EJ, Nguyen KK, Di M, Shetterly S, Tang J, Yeh WC, Schwarz M, Jukema JW, Scott R, Wasserman SM, Princen HM, Jackson S.
    J Lipid Res; 2014 Nov 15; 55(11):2370-9. PubMed ID: 25258384
    [Abstract] [Full Text] [Related]

  • 17. PCSK9-mediated degradation of the LDL receptor generates a 17 kDa C-terminal LDL receptor fragment.
    Tveten K, Str M TB, Berge KE, Leren TP.
    J Lipid Res; 2013 Jun 15; 54(6):1560-1566. PubMed ID: 23509406
    [Abstract] [Full Text] [Related]

  • 18. MG132, a proteasome inhibitor, enhances LDL uptake in HepG2 cells in vitro by regulating LDLR and PCSK9 expression.
    Yan H, Ma YL, Gui YZ, Wang SM, Wang XB, Gao F, Wang YP.
    Acta Pharmacol Sin; 2014 Aug 15; 35(8):994-1004. PubMed ID: 25042549
    [Abstract] [Full Text] [Related]

  • 19. Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9.
    Romagnuolo R, Scipione CA, Marcovina SM, Gemin M, Seidah NG, Boffa MB, Koschinsky ML.
    PLoS One; 2017 Aug 15; 12(7):e0180869. PubMed ID: 28750079
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.